Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 81 of 6351
-
Mpox vaccine trial for pregnant women launches in congo
Vaccine OngoingThis Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be c…
Phase 3 • Sponsor: Jean-Pierre Van geertruyden • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
Fetal balloon surgery may boost survival in severe birth defect
Disease control Recruiting nowThis registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o/e LHR \< 30%, or isolated right CDH and o/e LHR ≤ 45%, compared to those receiving standard care. This prospective regist…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a new PET tracer light up Alzheimer's plaques in the living brain?
Diagnosis Recruiting nowA multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using \[18F\]Fluorbetazine injection.
Phase 3 • Sponsor: HTA Co., Ltd. • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a Dual-Antibody combo outsmart advanced lung cancer?
Disease control OngoingThis study targets patients with in first-line treatment of advanced NSCLC, enrolling 60-84 participants. Patients will receive Arm 1: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Pemetrexed (500 mg/m2 IV, D1) + a platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1), Q3W, for 4 c…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New 2-Month TB pill cocktail could replace 6-Month regimen
Disease control Recruiting nowTuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-…
Phase 3 • Sponsor: Shenzhen Third People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a One-Two punch of radiation and immunotherapy tame pancreatic cancer?
Disease control Recruiting nowThe purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with met…
Phase 2 • Sponsor: Benjamin Spieler • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a 15-Minute test stop a deadly virus in its tracks?
Diagnosis CompletedBackground Crimean-Congo Haemorrhagic Fever (CCHF) is a rare disease with a death rate between 10% and 50%, rising to 80% during outbreaks. There are no approved drugs or vaccines, and existing treatments only work if given early. Current diagnosis is slow (2-5 days), delaying tr…
Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
Brain cell transplant trial aims to give Parkinson's patients more good hours each day
Disease control Recruiting nowStudy BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Phase 3 • Sponsor: BlueRock Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Gene-Edited immune cells take on aggressive brain tumors
Disease control Recruiting nowThis phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of imp…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a new vaccine shield infants from dengue?
Vaccine Recruiting nowDengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The purpose of this study is to collect information of vaccination with TDV when given to children younger than 2 years. The main aims of…
Phase 3 • Sponsor: Takeda • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
Can a custom vaccine train the body to fight prostate cancer?
Vaccine Stopped earlyTumor antigens are protein fragments produced by cancer cells carrying genetic mutations, and many tumor antigens are similar to normal protein antigens, making them unrecognizable by the immune system. Many tumor vaccines are prepared based on a single tumor antigen. This study …
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Vaccine
Last updated Aug 26, 2026 00:00 UTC
-
New hope for High-Risk breast cancer: drug combo aims to stop recurrence
Disease control Recruiting nowThis study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4/6 inhibitors has demonstrated greater clinical benefits for advanced TPBC patients.…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refr…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Massive dengue vaccine trial for kids launches – could it stop the virus?
Vaccine Recruiting nowThe purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in ch…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Could a drug combo tame deadly pancreatic cancer?
Disease control Recruiting nowThis is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the a…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may spare throat cancer patients from full radiation
Disease control Recruiting nowThis study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
Sponsor: Indiana University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
Disease control OngoingEvaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Phase 1/2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Hope for FSHD: new drug enters final stage of testing
Disease control Recruiting nowA Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug aims to unlock speech in angelman syndrome
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cooling Newborns' brains: a lifesaving hope for Oxygen-Deprived babies?
Disease control Recruiting nowThis study aims to evaluate the effectiveness of therapeutic hypothermia in neonates diagnosed with hypoxic-ischemic encephalopathy (HIE). The study focuses on assessing both short-term outcomes after treatment and long-term neurological outcomes following therapeutic hypothermia…
Sponsor: National Children's Hospital, Vietnam • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC